Roivant Sciences Ltd. 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-25 07:19 am Unchanged |
2025-02-21 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 20.500% |
0 (Unchanged) |
Filing |
| 2025-02-18 5:21 pm Unchanged |
2025-02-18 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 20.500% |
0 (Unchanged) |
Filing |
| 2021-10-20 5:13 pm Purchase |
2021-10-18 | 13D | Arbutus Biopharma Corporation ABUS |
Roivant Sciences Ltd. ROIV |
38,847,462 29.100% |
22,833,922 (+142.59%) |
Filing |